Smartphone Go/No-Go Task in Multiple Sclerosis
A study analyzed the Go/No-Go task's ability to distinguish health and disease states among 303 individuals, finding it identified differences between healthy donors and MS patients primarily through response latency. The task displayed poor-to-moderate reliability and ultimately was excluded from a neurological testing suite due to redundancy with simpler metrics.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
The findings indicate that while the Go/No-Go task can reflect processing speed impairments in MS, its ability to offer new diagnostic insights is limited compared to existing measures.
What this does not prove
The study did not establish longitudinal reliability for the Go/No-Go task, and its discriminative abilities are redundant with simpler reaction time metrics, undermining its clinical utility.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 303 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- No
- Relevant MS type
- Not reported
- Publication date
- 2026-09-11
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceProcessing Speed Accounts for the Discriminative Power of a Smartphone Go/No-Go Task in Multiple Sclerosis. ↗DOI: 10.64898/2026.09.09.26362640
Supporting passages (10)
study phaseConsequently, the Go/No-Go module was excluded from NeuFun-TS to minimize patient testing burden without compromising diagnostic sensitivity.
study designSmartphone technology provides a scalable alternative capable of extracting distinct digital biomarkers from continuous sensor and event streams.
subjectsWe analyzed 3,270 quality-controlled trials from 303 participants, focusing primary analyses on 488 first-trial observations across 34 healthy donors (HD) and 213 multiple sclerosis (MS) participants.
sample sizeFollowing the integration of several cognitive modules into the self-administered Neurological Functions Test Suite (NeuFun-TS), this study evaluates the clinical utility and incremental validity of a final candidate module: an equiprobable (50/50) continuous vigilance Go/No-Go paradigm.
primary endpoint metRESULTS: Although nine of the 10 outcomes significantly separated HD from MS and seven separated relapsing-remitting from progressive MS subtypes (all adjusted p < 0.05), discriminative power was driven almost entirely by response latency rather than commission errors or inhibitory metrics.
publication datePublication date: 2026-09-11
interventionCONCLUSION: Although the smartphone-based Go/No-Go task reflects processing speed impairment in MS, its discriminative capability is redundant with simpler reaction time metrics already implemented in the platform.
primary endpointRESULTS: Although nine of the 10 outcomes significantly separated HD from MS and seven separated relapsing-remitting from progressive MS subtypes (all adjusted p < 0.05), discriminative power was driven almost entirely by response latency rather than commission errors or inhibitory metrics.
findingsMulti-predictor composite scores offered no diagnostic advantage over reaction time alone.
limitationsConsequently, the Go/No-Go module was excluded from NeuFun-TS to minimize patient testing burden without compromising diagnostic sensitivity.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.